Pfizer says antiviral pill cuts risk of severe Covid by 89pc
NEW YORK: A trial of Pfizer Inc's experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalisation or death for adults at risk of developing severe disease, the company said on Friday.The results appear to surpass those seen with Merck & Co Inc's pill, molnupiravir, which was shown last month to...